Medical oncologists review the FLAURA2 study looking at osimertinib with or without chemotherapy in EGFR-mutated NSCLC and discuss patients for whom they would consider the therapy.
NVL-655 Receives FDA Breakthrough Therapy Designation in ALK+ NSCLC
Data from the phase 1/2 ALKOVE-1 trial support the breakthrough therapy designation for NVL-655 in advanced ALK-positive non–small cell lung cancer.
Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery
Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.
Lifileucel Yields Responses in Metastatic Non–Small Cell Lung Cancer
Phase 2 data support additional investigation of lifileucel as a treatment for patients with metastatic non–small cell lung cancer.
Combatting Stigmatization to Increase Lung Cancer Screening Access
Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN, discusses how LungTalk, a health communication and decision support tool, may spread awareness and knowledge surrounding lung cancer screening.
T-DXd Yields Consistent Results in HER2-Overexpressing NSCLC
T-DXd given at 2 dose levels continued to show anti-tumor activity in patients with HER2-overexpressing non–small cell lung cancer.
Glecirasib Shows Promising Efficacy in KRAS G12C+ Advanced NSCLC
Those who have been previously treated for KRAS G12C–mutated advanced NSCLC may benefit from treatment with glecirasib.